Overview

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

Status:
Completed
Trial end date:
2023-09-27
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults. Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.
Phase:
Phase 1
Details
Lead Sponsor:
Emergent BioSolutions
Treatments:
Brincidofovir